 SAN DIEGO, Oct. 08, 2021 GLOBE NEWSWIRE -- Cidara Therapeutics, Inc. Nasdaq: CDTX, a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 14,838,706 shares of its common stock at a price to the public of 1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of 15.50 per share. The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be 35.0 million. 